Nieuws en video's - FEMASYS INC. - Engels

ATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the American Society of Reproductive Medicine’s (ASRM) 2024 Scientific Congress and Expo, being held October 19-23 in Denver, Colorado. The Company will be showcasing its solutions...

ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at...

ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribution partners after successfully completing its first commercial FemaSeed ® procedures in Europe. Members of the Femasys team traveled to Madrid...

ATLANTA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces the onboarding of the first infertility medical clinic customers to offer its FemaSeed infertility treatment to patients in California and Florida. “Femasys has begun partnering with infertility centers across the...

ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has secured strategic distribution partnerships for its CE-marked products, including FemaSeed ® and FemVue ® in Spain. Comercial Medico Quirurigca, SA (CMQ) will distribute the products in northern...

ATLANTA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for FemChec ® , an innovative diagnostic solution for checking the fallopian tubes, designed for controlled delivery of...

ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the Canadian Fertility and Andrology Society’s (CFAS) 70 th Annual Meeting, to be held September 12-14, 2024 at The Westin Bayshore, Vancouver, British Columbia. The Company will...

ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the H.C. Wainwright 26 th Annual Global Investment Conference. The fireside chat will be hosted by Emily Bodnar, Life Sciences...

ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces that it has received CE mark certification and product approval from Health Canada, the Public Health Agency of Canada, for its compact, eco-friendly FemVue® MINI for fallopian tube assessment. “Our mission at Femasys has...

ATLANTA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, hosted Congresswoman Lucy McBath, Georgia’s 7 th district representative to the U.S. House of Representatives, for an informative tour of the Company’s facility headquartered in Suwanee, Georgia. Femasys Founder, President and...

ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended June 30, 2024 and provides a corporate update. Corporate Highlights from 2Q 2024 to date Company received European Union Medical Device Regulation (EU MDR) certification and CE Mark...

ATLANTA, June 27, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it will be participating at the European Society of Human Reproduction and Embryology’s (ESHRE) 40 th Annual Meeting in Amsterdam on July 7-10. The Company will be exhibiting at booth #11,111. The conference follows...

ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for four of its products. The four products – FemaSeed ® , FemVue ® , FemCerv ® , and FemCath ® – are...

ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces CEO and Founder Kathy Lee-Sepsick has met with staff from the White House Office of Science and Technology Policy (OSTP) to discuss the President and First Lady’s Cancer Moonshot and the Company’s FemCerv ® product....

ATLANTA, May 16, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces CEO and Founder Kathy Lee-Sepsick met with the White House’s Gender Policy Council (GPC) staff to discuss the Company’s reproductive health products and the future of women’s health in the United States. According to...

-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc ® for permanent non-surgical birth control continues -- ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2024 and provides...

ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces the expansion of its commercial management team, marking a significant milestone in the company's mission to advance women's health worldwide. With the addition of new team members to its commercial team in key...

ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces its CEO and Founder Kathy Lee-Sepsick has met with several members of Congress to discuss the current women’s healthcare landscape. Further, Lee-Sepsick is raising awareness of Femasys and the status of its...

ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the year ended December 31, 2023 and provides a corporate update. Corporate Highlights from 4Q 2023 to date Company announced positive topline data from pivotal trial for FDA-cleared FemaSeed ® for...

ATLANTA, March 21, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing the significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, invites investors to join management in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which...